Zinger Key Points
- Last month, Novo Holdings, the major shareholder of Novo Nordisk, said it plans to ramp up its annual investments to $7 billion by 2030.
- Expected to commence pilot projects by year-end, Gefion will be stationed in Denmark for the public and private sectors to access.
Novo Nordisk A/S NVO, the maker of popular diabetes and weight loss drugs like Ozempic and Wegovy, is delving into artificial intelligence.
Backed by the Novo Nordisk Foundation, Eviden, a French computing company, is set to construct a supercomputer leveraging Nvidia Corp’s NVDA AI technology.
Cédric Bourrasset, Eviden’s quantum computing chief, anticipates the supercomputer, dubbed Gefion, will revolutionize drug discovery and healthcare solutions, offering speed and efficiency.
Expected to commence pilot projects by year-end, Gefion will be stationed at Denmark’s newly established National Centre for AI Innovation and will provide researchers from Denmark’s public and private sectors access to an advanced supercomputer optimized for AI.
This venture enjoys the support of tech giants Nvidia, valued at a staggering $2.21 trillion, and Novo Nordisk, a pharmaceutical powerhouse boasting a market value surpassing even Tesla.
Leveraging Nvidia’s latest chip technology, Gefion is poised to redefine the landscape of scientific inquiry, particularly in drug development and disease management.
The Novo Nordisk Foundation’s strategic investment in this initiative underscores its commitment to advancing medical science. Bolstered by the success of Ozempic and Wegovy, the foundation aims to drive innovation further, capitalizing on AI’s potential to expedite breakthroughs.
This vision aligns with recent advancements, such as Microsoft Corp’s MSFT collaboration with the Pacific Northwest National Laboratory, where AI facilitated the discovery of new battery materials within weeks, which traditionally took years.
Last month, Novo Holdings, the major shareholder of Novo Nordisk, said it plans to ramp up its annual investments to $7 billion by 2030.
The investment firm, which manages the assets of the Novo Nordisk Foundation, intends to increase its annual investments from $3 billion in 2023 to $7 billion by 2030.
Price Action: NVO shares are down 0.59% at $129.06 on the last check Friday.
Image By Natalia Varlei On Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
